摘要
目的探讨布地奈德对轻度持续性支气管哮喘患儿的治疗作用及机制。方法选取120例轻度持续性支气管哮喘患儿,采用抽签方法随机分为布地奈德组和孟鲁司特组,各60例,两组患儿均采用对应药物连续治疗8周后评价临床症状、气道炎症、血清基质金属蛋白酶(MMP)。结果治疗后,布地奈德组患儿的日间、夜间症状评分均低于孟鲁司特组,差异有统计学意义(P<0.05),布地奈德组患儿血清金属蛋白酶-9(MMP-9)、金属蛋白酶-2(MMP-2)、白细胞介素-17(IL-17)、白细胞介素-33(IL-33)、嗜酸性粒细胞(EOS)均低于孟鲁司特组,差异有统计学意义(P<0.05);治疗后,布地奈德组患儿的控制率95.00%高于孟鲁司特组的83.33%,差异有统计学意义(P<0.05)。结论布地奈德治疗轻度持续性支气管哮喘患儿能更加显著的减轻患儿的气道炎性反应、改善临床症状、提高治疗效果。
Objective To explore the mechanism of budesonide treatment effect in children with mild persistent asthma. Methods120 patients with mild persistent asthma in children were selected,using the lottery method divided into budesonide group and montelukast group with 60 cases in each group randomly. Two groups of patients were treated with corresponding drugs for 8 weeks after the evaluation of clinical symptoms,airway inflammation,serum MMP. Results After the treatment,budesonide group daytime symptom scores were lower than the montelukast group,the differences were statistically significant( P < 0. 05). The serum MMP-9,MMP-2,IL-17,IL-33 and EOS in budesonide group children were lower than the montelukast group,the differences were statistically significant( P< 0. 05). After the treatment,the control group with the rate of 95% was higher than that of budesonide montelukast group 83. 33%,the difference was statistically significant( P < 0. 05). Conclusions Budesonide in the treatment of children with mild persistent asthma can improve airway inflammation,relieve the patients more obvious clinical symptoms,improve the therapeutic effect.
出处
《安徽医药》
CAS
2017年第10期1861-1864,共4页
Anhui Medical and Pharmaceutical Journal
